Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.
Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.
Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.
Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.
Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.
Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.
The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.
Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.
VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.